ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Termination of a Material Definitive AgreementItem 1.02. Termination of a Material Definitive Agreement.
On November 22, 2016, Adaptimmune Therapeutics plc (the “Company”) received notices from Immunocore Limited (“Immunocore”) to end subleases of Building 91, Milton Park, Oxfordshire (“Building 91”) effective June 1, 2017.
The formal termination of these subleases is part of a plan, which the Company has worked on in collaboration with Immunocore, to ensure the smooth transition of the Company’s staff from Building 91 into the Company’s new 67,100 square foot building at Milton Park, Oxfordshire (“Building 60”) in the first half of 2017. Building 60 comprises laboratory and office space and has been designed to accommodate the Company’s research and development and U.K. corporate operations.
As previously reported, the Company entered into a lease of Building 60 directly with MEPC Milton Park, the owner of Milton Park, on October 24, 2016, following the completion of the building and to a lease agreement between the Company and MEPC Milton Park.
